PepGen Inc. (NASDAQ: PEPG) had itself a Tuesday. The clinical-stage biotech's stock surged 111.30% to $5.05 at the time of publication, and the trading volume tells you everything about the market's reaction: 31.855 million shares changed hands compared to an average volume of 983.011 thousand, according to market data.

The catalyst was positive topline results from the Phase 2 FREEDOM2-DM1 study, which showed significant splicing correction and functional gains in patients with myotonic dystrophy type 1, a rare muscular disorder. In plain English, the company may have found a way to fix the genetic glitch at the heart of the disease, and the early numbers are hard to ignore.

The timing matters, too. Dyne Therapeutics Inc. (DYN) is nearing completion of a pivotal trial, while Novartis AG (NVS) recently reported a Phase 3 trial failure for its acquired DM1 candidate, creating sector uncertainty. Against that backdrop, PepGen's data landed like a thunderclap.

Record Splicing Correction In Muscle Tissue

Here's the headline number: patients who received the 10 mg/kg dose achieved a 46.5% average muscle splicing correction at Week 13. The pooled placebo arm averaged just 6.8%. Five of the six treated patients achieved greater than 20% correction, while four surpassed 50%.

The company stated that these outcomes mark the highest level of splicing correction ever reported in a multiple-dose trial for the rare genetic condition. That is a bold claim, but the gap between treated and placebo patients gives it some weight.

Notable Functional And Mobility Improvements

Splicing correction is the biology story. The functional data is the human story, and it held up through Week 16 across several assessments.

Video Hand Opening Time, an objective measure of myotonia, improved by 3.9 seconds, or approximately 52.7%, while the placebo arm improved by just 0.2 seconds. Investigators also documented dose-dependent splicing correction of CLCN1, a primary driver of myotonia. Patients registered a 16.2% improvement in hand grip strength.

Mobility tests showed further progress, with the Timed Up and Go assessment improving by 8.5% and the 10-Meter Walk/Run Test gaining 6.8%. Patient-reported outcome measures yielded inconclusive results at Week 16, displaying favorable directional trends on one scale alongside mixed results on another. So not every metric cooperated, but the objective measures did the heavy lifting.

Strong Safety Profile And Competitive Outlook

The 10 mg/kg regimen demonstrated favorable tolerability with no severe adverse events, treatment discontinuations, or cumulative kidney toxicity. Researchers noted mild nausea as the most common side effect, alongside four mild instances of elevated urine protein that resolved with subsequent doses. For a rare disease drug that patients would take repeatedly, that kind of clean safety read matters as much as the efficacy numbers.

PepGen expects to release clinical results from its fully enrolled 12.5 mg/kg cohort in the first half of 2027. The drugmaker also plans to share open-label extension data in January 2027. Those catalysts will determine whether Tuesday's move is a one-day wonder or the start of something bigger.

PEPG Price Action: PepGen shares were up 111.30% at $5.05 at the time of publication on Tuesday, according to market data.